A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial - PACE-CME

A rise in adverse clinical events with NOACregime after TAVR resulted in termination of trial

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Improved health status with SGLT2-inhibitor in HFrEF
Improved health status with SGLT2-inhibitor in HFrEF
AHA 2019
Improved health status with SGLT2-inhibitor in HFrEF
- Prof. Mikhail Kosiborod
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
AHA 2019
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
AHA 2019
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
- Prof. Donald Lloyd-Jones
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
AHA 2019
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
- Scott Solomon, MD